Insider Buying: Apollomics (NASDAQ:APLM) CFO Purchases $400,005.00 in Stock

Apollomics Inc. (NASDAQ:APLM) CFO Peter Kuan-How Lin acquired 26,667 shares of the business’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $15.00 per share, with a total value of $400,005.00. Following the completion of the acquisition, the chief financial officer owned 48,979 shares in the company, valued at approximately $734,685. This represents a 119.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apollomics Trading Down 0.2%

Shares of Apollomics stock traded down $0.04 on Monday, hitting $23.36. 35,072 shares of the company traded hands, compared to its average volume of 30,338. Apollomics Inc. has a 52 week low of $3.66 and a 52 week high of $42.12. The business has a 50-day simple moving average of $18.24 and a 200 day simple moving average of $17.30.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Apollomics has a consensus rating of “Sell”.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new position in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent reporting period. Institutional investors and hedge funds own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.